06:19 EDT BeiGene (ONC) sees FY25 revenue $4.9B-$5.3B, consensus $5.09B
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeiGene says USPTO invalidates Pharmacyclics’ ‘803 patent
- Reddit initiated, Roku upgraded: Wall Street’s top analyst calls
- BeiGene initiated with an Outperform at RBC Capital
- BeiGene’s Strategic Positioning and Growth Potential: A Buy Recommendation by Reni Benjamin
- BeiGene to discontinue development program for ociperlimab (BGB-A1217)